26 April 2024
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU NO. 596/2014) AS IT FORMS PART OF
MOLECULAR ENERGIES PLC
("Molecular" or the "Company")
Last Day of Dealings on AIM
Post Cancellation Shareholder Communications
Molecular Energies plc (AIM: MEN), provides an update on the matters described in the circular to shareholders dated 28 March 2024 and further information on shareholder communication following cancellation of the admission of the Company's ordinary shares to trading on AIM ("Cancellation").
Cancellation of admission to AIM
Cancellation will take place at 7.00 a.m. on 29 April 2024. The final day of dealings in the Company's shares on AIM is today, 26 April 2024.
Website
The current format of the website of the Company will be re-structured and will be live with effect from 1 May 2024.
The website will provide up to date information with regard to all material developments of the Company and members of its group. Whilst some sections of the current website will no longer be applicable, in order to promote transparency as a private company new features will be added with the aim of strengthening the connection between the Company and its remaining shareholders.
Communication
Molecular recognises that as a private company, it is imperative to ensure that those who came on its journey are kept regularly informed.
Accordingly, Molecular will publish news of all material developments both on its website and via its social media accounts, which it will continue to maintain. A regular newsletter providing business updates will be issued with the first anticipated by 30 September 2024, by which date the Company anticipates that it will publish its annual accounts for the year ended 31 December 2023. The Company will maintain its shareholder communications email address - info@molecularenergiesplc.com - and investors wishing to receive these regular updates or enter into dialogue with the Company are encouraged to email that address requesting to sign up.
Dealing Arrangements
The Company's ordinary shares will be admitted to trading on the JP Jenkins securities matching platform from the 29 April 2024.
JP Jenkins provides a securities matching venue for unlisted or unquoted assets in companies, enabling shareholders and prospective investors to buy and sell shares on a matched bargain basis. JP Jenkins is a trading name of InfinitX Limited and Appointed Representative of Prosper Capital LLP (FRN453007).
Shareholders wishing to trade these securities can do so through their stockbroker. Trades will be conducted at a level that JP Jenkins is able to match a willing seller and a willing buyer. Trades can be conducted, and limits can be accepted, during normal business hours. Shareholders or potential investors can place limits via their existing
The indicative pricing for the ordinary Shares (ISIN: GB00BMT80K89), as well as the transaction history, will be available on the JP Jenkins website at (https://jpjenkins.com/company/molecular-energies/).
The provision of the matched bargain facility will be kept under review by the Board and, in determining whether to continue to offer a matched bargain facility, the Company shall consider expected (and communicated) shareholder demand for such a facility as well as the composition of the Company's register of members and the costs to the Company and shareholders.
Molecular Energies PLC Peter Levine, Chairman Rob Shepherd, Group FD |
+44 (0)20 7016 7950 |
Cavendish Capital Markets Limited (Nominated Adviser & Broker) Simon Hicks George Dollemore |
+44 (0)20 7220 0500 |
Tavistock (Financial PR & IR) Simon Hudson, Nick Elwes, Saskia Sizen |
+44 (0)20 7920 3150 |
JP Jenkins (Matched Bargain Settlement Facility) Veronika Oswald - Director |
+44 (0)20 7469 0937 |
For the purposes of MAR, Article 2 of Commission Implementing Regulation (EU) 2016/1055 and the
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.